Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

WESTON, Fla. and ANN ARBOR, Mich., April 20, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions,

Related Keywords

Michigan ,United States ,Casey Mcdonald ,Stepheng Marcus ,Jon Nugent ,Salim Hayek ,Frankel Cardiovascular Center ,University Of Michigan Health ,Cantex Pharmaceuticals Inc ,Kellogg Eye Center ,University Of Michigan ,Rogel Cancer Center ,Prnewswire Cantex Pharmaceuticals Inc ,Nasdaq ,University Hospital ,Tv Therapeutics Inc ,Michigan Medicine ,Medical Director ,Michigan Health Frankel Cardiovascular Center ,Chief Executive Officer ,Cantex Pharmaceuticals ,Um Medical ,Um Medical School ,Michigan Health ,Von Voigtlander Women ,Michigan Health West ,Rogel Cancer ,Covid 19 ,